Clinical Trial Update: Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 [NA]

View source ↗

Summary

A pilot study of Brentuximab Vedotin in relapsed/refractory CD30-positive Peripheral T-Cell Lymphoma was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Adcetris (brentuximab vedotin) (brentuximab vedotin)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Peripheral T-Cell Lymphoma | NA | Status: TERMINATED | Results posted: 2017-01-19